Filing Flows › Financials › HeartSciences (HSCS)
HeartSciences (HSCS) earnings and revenue breakdown
Latest: Q1 FY27 · 10-Q filed Sep 14, 2026 · HeartSciences (HSCS) Q1 FY27 earnings results →
Q1 FY27 Revenue up 10% year over year to $2K
HeartSciences made $2K in Q1 FY27 (+10% Y/Y). Operating margin n/m, net loss $3.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Sep 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $2K in Q1 FY27, up 11% year over year.
Gross margin was 63.8%, up 3.8 points from Q1 FY26. Operating costs exceeded revenue by $2.9M, an operating margin of -139956.7%. Operating expenses grew 57% against revenue growth of 11%. The fastest-growing cost line was SG&A (+132%). The quarter ended with a net loss of $3.2M.
Operating cash flow was −$1.3M. Non-cash charges added back $6K of depreciation and $739K of share-based compensation. Working capital and other items added $1.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 FY27 | 10-Q | Sep 14, 2026 | $2K | +10% | n/m | −$3.2M | −$1.3M |
| Q2 FY26 | 10-Q | Dec 15, 2025 | $2K | — | n/m | −$2.4M | −$2.3M |
| Q1 FY26 | 10-Q | Sep 11, 2025 | $2K | — | n/m | −$2.1M | −$2.0M |
| Q4 FY25 | 10-K | Jul 24, 2025 | $4K | — | n/m | −$2.1M | −$1.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About HeartSciences
We are a healthcare information technology company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”). Our first commercial product is MyoVista Insights™, a cloud-native, vendor- and device-agnostic ECG management platform designed to modernize ECG workflows and enable scalable deployment of AI-ECG capabilities across healthcare systems. MyoVista Insights™ is classified as a Medical Device Data System (“MDDS”) and is exempt from the FDA 510(k) requirements. The platform is designed to streamline ECG study organization, enhance waveform analysis, and simplify clinical workflows, enabling more efficient interpretation, storage, and management of ECG data.
In its own words, from its annual report, filed Jul 23, 2026.
HeartSciences against its Finance Services peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +10% against the peers' median +17%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| HSCS HeartSciences | Q1 FY27 | $2K | +10% | n/m |
| AXP American Express | Q3 2026 | $20.1B | +9% | 22.6% |
| BTGO Bitgo Holdings | Q2 FY27 | $4.3B | +80% | -0.4% |
| General Motors Financial Company | Q3 2026 | $4.3B | -0.6% | 15.3% |
| SOFI SoFi Technologies | Q3 2026 | $1.4B | +44% | 22.9% |
| COIN Coinbase Global | Q3 2026 | $1.2B | -35% | 5.1% |
| CRCL Circle Internet Group | Q3 2026 | $865M | +17% | 24.1% |
| CHYM Chime Financial | Q3 2026 | $718M | +32% | 4.8% |
| GDOT Green DOT | Q2 2026 | $596M | +18% | -0.1% |
Source: HeartSciences 10-Q on SEC EDGAR · CIK 1468492 · Finance Services
13F: who owns HSCS and who is buying
More on HSCS
History
Every quarter: Q1 FY27 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results